Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of both early and advanced cutaneous T-cell lymphoma (CTCL). Although bexarotene has been used for decades in the treatment of CTCL, little is known about the mechanisms underlying...

Full description

Bibliographic Details
Main Authors: Kayo Tanita, Taku Fujimura, Yota Sato, Chunbing Lyu, Yumi Kambayashi, Dai Ogata, Satoshi Fukushima, Azusa Miyashita, Hideki Nakajima, Motoki Nakamura, Akimichi Morita, Setsuya Aiba
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-09-01
Series:Frontiers in Oncology
Subjects:
advanced CTCL
bexarotene
tumor-associated macrophages
CCL22
immunomodulation
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00907/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00907/full

Similar Items